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Background: The prospect of eliminating malaria is challenged by emerging insecticide resistance and vectors with
outdoor and/or crepuscular activity. Ivermectin can simultaneously tackle these issues by killing mosquitoes feeding
on treated animals and humans. A single oral dose, however, confers only short-lived mosquitocidal plasma levels.
Methods: Three different slow-release formulations of ivermectin were screened for their capacity to sustain
mosquito-killing levels of ivermectin for months. Thirty rabbits received a dose of one, two or three silicone implants
containing different proportions of ivermectin, deoxycholate and sucrose. Animals were checked for toxicity
and ivermectin was quantified periodically in blood. Potential impact of corresponding long-lasting formulation
was mathematically modelled.
Results: All combinations of formulation and dose released ivermectin for more than 12 weeks; four combinations
sustained plasma levels capable of killing 50% of Anopheles gambiae feeding on a treated subject for up to 24 weeks.
No major adverse effects attributable to the drug were found. Modelling predicts a 98% reduction in infectious vector
density by using an ivermectin formulation with a 12-week duration.
Conclusions: These results indicate that relatively stable mosquitocidal plasma levels of ivermectin can be safely
sustained in rabbits for up to six months using a silicone-based subcutaneous formulation. Modifying the formulation
of ivermectin promises to be a suitable strategy for malaria vector control.
Keywords: Vector control, Malaria, Malaria elimination, Ivermectin, Slow release, Anopheles gambiae, Silicone, Residual
transmission, Outdoor transmissionBackground
Increased funding and political commitment have led to
outstanding worldwide achievements in malaria control
over the last 14 years. The estimated malaria mortality
rate in children under five has almost been halved
worldwide since 2000 and it is projected to decrease by
61% by 2015 [1]. Yet, malaria is still a formidable public
health problem that caused an estimated 198 million
cases and 584,000 deaths in 2013 [1]. In many settings,
there has been a renewed interest for malaria elimin-
ation [2], and the general mood is that of ‘impatient op-
timism’ [3]. This general optimism has translated into
more concrete research [4] and operational [5] agendas* Correspondence: cchaccour@unav.es
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unless otherwise stated.to decrease malaria transmission until eradication. The
main determinants of malaria transmission are mosquito-
related variables [6]; vector control plays a central role in
control strategies [7]. It has been the most successful
intervention in the past [8] and it is likely to remain so in
future elimination endeavours.
The malERA consultative group on vector control
identified three main challenges to eradication [9]: 1) the
emergence of insecticide resistance affecting all major
vector species and all classes of insecticides in two-
thirds of endemic countries [7]; 2) the presence of
outdoor-biting/resting mosquitoes, not readily targeted
by insecticide-treated nets (ITNs) and indoor-residual
spraying (IRS) [10,11]; and, 3) the need for new ap-
proaches to achieve elimination in areas where vectors
exhibit a particularly high vectorial capacity. Additional
problems include the selection of vectors with early orral. This is an Open Access article distributed under the terms of the Creative
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[12,13], vector biodiversity and environmental change [14].
One additional source of concern for eradication is the
emergence of artemisinin resistance in Southeast Asia.
The historic perspective is unsettling as this area has re-
peatedly been the epicentre from where resistance to
anti-malarial drugs has spread to Africa and the rest of
the world [15]. An emergency containment plan is in
place [16] and even focal elimination of all falciparum
malaria has been advocated [17,18]. One further prob-
lem is that the main local malaria vectors, Anopheles
dirus and Anopheles minimus, show substantial outdoor
feeding and biting [19] as well as crepuscular activity
and a tendency to bite early at night [20], which limits
the effectiveness of ITNs and IRS. Additional vector
control methods are urgently needed in the region [19].
Ivermectin (IVM) is a systemic insecticide that reduces
the survival of mosquitoes feeding on treated humans,
both under laboratory [21,22] and field conditions [23],
potentially leading to a disruption in malaria transmis-
sion [24]. Mass drug administration (MDA) with IVM
has been advocated as a complementary vector control
strategy [25,26]. Potential benefits include: i) a novel
mechanism of action [27] compared to currently used
insecticides, which could circumvent resistance; ii) ef-
fectiveness against malaria vectors regardless of place or
time of the feeding; and, iii) additional effects inhibiting
Plasmodium sporogony [28].
All these characteristics make MDA with IVM a particu-
larly valuable intervention for the vectors in the Mekong
region and local elimination endeavours in the light of ar-
temisinin resistance. According to a recent mathematical
model [29], a key factor for interrupting transmission
would be the time IVM remains in blood above mosquito-
killing levels.
The lethal concentration 50 (LC50) is defined as the
blood levels needed in order to kill 50% of the mosqui-
toes feeding on a treated individual, its closest clinical
equivalent is the minimum inhibitory concentration used
in microbiology labs. The LC50 of IVM for Anopheles
gambiae in the first ten days after a blood meal has been
estimated by mixing human blood with a known dilution
of the drug in a tube and then performing a membrane
feeding essay. The LC50 estimated with this method
ranges from 14.6 to 26.9 ng/ml [22,28]. Recent evidence
from membrane feedings using blood drawn from iver-
mectin treated volunteers gives a much lower range of
4.69-7.51 ng/ml [30]. This discrepancy could be the result
of unknown active metabolites and possibly, blood meal
size differences between membrane and skin feeding
mosquitoes.
At the approved dose of 200 μg/kg, current oral for-
mulations can only maintain mosquitocidal concentra-
tions for approximately 48 hours [31,32]. Alternativesinclude a scheme with multiple doses over the course of
weeks, which poses logistical challenges, or the adminis-
tration of a slow-release formulation on one single en-
counter. Given IVM’s pharmacokinetic properties [33], a
slow-release oral tablet could only increase the time with
concentrations above LC50 in hours, while injectable,
depot formulations could do it for days to weeks. An im-
plantable subcutaneous device [34,35] could sustain key
mosquito-killing levels of IVM for months. Subcutane-
ous implants for contraceptive purposes were licensed
more than 30 years ago; they release small amounts of
hormones for years and have an excellent security profile
[36]. In developing countries suitable for the implemen-
tation of slow-release IVM formulations, the acceptance
of contraceptive implants is high [37] and seems to be
increasing [38].
The main goal of this work was to adapt the design of
an IVM slow-release formulation to make it suitable for
use in humans and peridomestic animals as an add-
itional malaria vector control intervention. For this,
three different IVM-containing silicone implant formula-
tions were screened at different doses in a proof-of-
concept animal model. Rabbits were chosen because their
weight allows for an easier dose extrapolation to larger
mammals.
Methods
The implants
The 40×2-mm implants consist of two concentric cylin-
ders (silicone-covered rod formulation). The external cy-
linder is a 100% silicone impermeable membrane; the
inner cylinder contains silicone and a mixture of IVM,
deoxycholate sodium (DOC) and sucrose (SUC). The
inner drug-containing matrix contacts the subcutaneous
tissue and fluids only at the ends, where the cylinders
are cross-sectioned (Figure 1). Water enters at each end,
dissolves the IVM-DOC-SUC mixture and creates micro-
channels in the inner core, allowing for a controlled release
of the drug.
IVM is a lipophilic drug. DOC and SUC modify the
solubility of IVM and change its release rate from the
microchannels in the core. Two previously used propor-
tions of IVM:DOC:SUC known to have an appropriate
release profile in mice [35] and dogs [34] were chosen.
An third formulation with a high proportion of DOC,
which markedly increases the release rate, was also in-
cluded. This resulted in a different total IVM content for
each formulation. The internal cylinder (1.8 × 40 mm) in
the implants allows for an elution surface of 5.08 sq mm
each (2 π r2). This surface increases arithmetically when
using higher doses (two or three implants). The total
IVM calculated content of each formulation can be seen
in Table 1. Implants were manufactured by Specialty
Silicone Fabricators (SSFAb) at their ISO 13485-certified
Figure 1 Implant’s design and measures. With the current measures, the elution surface of each implant is 6.28 sq mm (2 x π x 12). IVM: ivermectin;
DOC: deoxycholate; SUC: sucrose.
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manufacture started my mixing the silicone component
with the drug and excipients (DOC and SUC) and mold-
ing it in cylindrical shape to form the inner drug matrix
core. The outer high consistency rubber layer was ex-
truded separately and applied over the drug core to
complete the implants. See references [34,35] for a de-
tailed description of the production methods. The rods
were sterilized using an electron beam.
Procedures
See Table 2 for a timeline of all procedures. The subjects
were 30 male New Zealand white rabbits of 16 weeks of
age. The diet was limited to 250 g/day in an attempt to
keep the weight stable. The animals were kept in indi-
vidual cages. Appropriate environmental enrichment
was used. Rabbits were randomly marked in the ear with
numbers 1–30 by the provider. Animals were assigned
to each formulation (F, M, X) in numerical order. In
each formulation group, the rabbits were assigned to aTable 1 Composition and total ivermectin content of the
implants according to formulation
Formulation IVM DOC SUC Total IVM/rod
F 80% 13% 7% 29 mg
M 50% 33% 17% 18 mg
X 35% 55% 10% 13 mg
Calculations done using the volume of the inner rod (0.102 cc) and assuming
negligible changes in the density of silicone (1.16 g/cc) by adding the
IM-DOC-SUC powder.
IVM: ivermectin; DOC: deoxycholate; SUC: sucrose.subgroup receiving a dose of one, two or three rods (1F,
2F, 3F, 1M, 2M, 3M, 1X, 2X, 3X). Each subgroup con-
tained three animals (in total 27 intervention plus three
controls). Control animals received one, two or three
100% silicone rods. The rods were inserted subcutane-
ously between the scapulae by means of a Jadelle® trocar
under general anaesthesia. When more than one im-
plant was inserted, they were placed forming a ‘V’
shape.
After implantation, the animals were checked daily for
clinical signs of IVM toxicity such as sleepiness, ataxia
and increase in tone [39]. Blood for IVM quantification
was drawn weekly for the first 12 weeks, under sedation,
from the marginal ear vein. An interim analysis of
plasma levels was performed at 13 weeks and only
groups where all subjects maintained at least 10 ng/ml
for the whole period were continued until week 25.
Blood samples were taken monthly in the remaining
groups until euthanasia. IVM plasma levels were deter-
mined using a variation of a previously described HPLC-
FLD [40,41]. The method was validated in accordance
with the European Medicines Agency guidelines [42].
A comprehensive toxicological profile was performed,
reviewing the neurological, cardiovascular, respiratory,
haematologic, digestive, and urinary systems. For toxico-
logical analysis, additional blood was drawn at baseline
and at 12 and 24 weeks. Blood tests included full count,
coagulation panel, glucose, electrolytes, muscular and
liver enzymes, bilirubin, cholesterol, total proteins, and
albumin. A urinary dipstick test was performed before
euthanasia. Vital signs were assessed at baseline and in
Table 2 Timeline of procedures
Intervention Weeks
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
Implantation ●
Check up ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
Vital signs ● ● ● ●
ECG ● ● ● ●
Ophthalmoscopy ● ● ●
Toxicology samples ● ● ● ●
IVM PK samples ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
Interim analysis ●
Euthanasia (1/2F, 1/2M, 1X) ●
Euthanasia (3F, 3M, 2/3X) ●
IVM: ivermectin; PK: pharmacokinetics.
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ECGs and indirect ophthalmoscopic examination. QT
intervals in the ECG were corrected using Bazett’s for-
mula. Normal values for vital signs, ECG, haematology,
coagulation, and biochemistry were taken from the lit-
erature [43] and compared to the mean and 95% CI of
the baseline values.
Euthanasia was performed under sedation using T61®
(MSD) at 25 weeks. An experienced toxicologist per-
formed full macroscopic autopsies on all rabbits. All
procedures were reviewed and approved by the animal
experimentation ethics committee of the Universidad de
Navarra (Registry number CEEA/135-12).Pharmacokinetic calculations and statistics
Pharmacokinetic calculations were performed with
Mathematica, Version 8.0, Wolfram Research, Inc.,
Champaign, IL, USA (2010). Areas under the curve
(AUC) were calculated using the linear trapezoidal rule.
ANOVA and Chi square test were used to contrast the
AUC of the different formulation-dose combinations at
12 weeks and the role of the elution area of the implants
on the likelihood of maintaining IVM plasma level above
7 ng/ml (the estimated in vivo LC50) for the same period
of time. Furthermore, a univariate linear regression
model was performed to assess the capacity of the for-
mula (proportion of DOC x elusion surface) to predict
the AUC at 12 weeks.
Comparisons of vital signs and blood test results at
baseline and at 1 and 12 weeks after implantation
were done using T-test for paired samples. For com-
paring baseline results with those of 24 weeks, the
Wilcoxon paired test was used. Statistical analysis was
done with SPSS version 20.0.Mathematical modelling of potential impact
The mathematical model developed by Slater et al. [29]
was used to assess the potential impact of a long-lasting
IVM product on mosquito survival and malaria inci-
dence in humans. The model considered a formulation
capable of sustaining 8 ng/ml plasma levels for two, four,
eight, 12 or 24 weeks administered to 80% of the popula-
tion over five years of age. This concentration is calculated
to increase the daily hazard of mortality to mosquitoes by
4.4 times, resulting in the mean lifespan of a mosquito in
the wild decreasing from 7.6 days [44] to 1.7 days.Results
Plasma levels and pharmacokinetics
All combinations of formulation and dose released IVM
for more than 12 weeks. Table 3 shows the median and
range of main pharmacokinetics (PK) parameters in the
different groups. Figure 2 shows the PK curves of the
four groups that maintained IVM levels of at least
10 ng/ml for the first 12 weeks. These were selected to
continue until week 25 (3F, 3M, 2X, 3X).
Using ANOVA, a statistically significant difference in
the AUC at 12 weeks between groups with different
elution surface (dose) was found. Additionally, the Chi
square test shows a significant difference in the like-
lihood of maintaining plasma levels above 7 ng/ml
between the same groups. Neither of the tests dem-
onstrates statistically significant differences in the
same parameters when comparing groups with dif-
ferent formulations (DOC and SUC proportions)
(Table 4). The linear regression model shows that
the AUC at 12 weeks can be predicted using the
product of the DOC proportion and the implant’s
elusion surface (DOC% x surface). An increase of
Table 3 Main pharmacokinetic parameters of all groups
Group Mean daily dose Tmax Cmax AUC 12 weeks AUC 24 weeks Time >7 ng/ml
1 F 64 (60–77) 2 (1–2) 7 (7–10) 66 (61–68) - 3 (1–3)
2 F 76 (75–105) 1 (1–2) 16 (12–16) 120 (113–163) - 12 (11–12)
3 F 75 (70–85) 1 (1–2) 22 (19–36) 155 (153–348) 277 (266–615) 24 (24)
1 M 34 (31–43) 7 (7–11) 13 (4–20) 81 (38–126) - 3 (0–11)
2 M 83 (77–91) 2 (1–3) 16 (14–20) 122 (106–164) - 12 (8–12)
3 M 69 (63–73) 1 (1–2) 22 (16–33) 164 (160–224) 300 (278–403) 24 (24)
1X 30 (29–32) 3 (2–8) 12 (8–14) 79 (63–85) - 2 (1–3)
2X 30 (27–34) 4 (3–4) 17 (17–35) 170 (152–311) 218 (207–404) 12 (12–16)
3X 43 (41–49) 3 (2–7) 42 (35–85) 307 (306–497) 422 (393–620) 16 (16)
For all values median and range are given. Mean daily dose (μg/kg/day), Tmax (weeks), Cmax (ng/ml), AUC (ng · week/ml), Time above 7 ng/ml (weeks).
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crease in the AUC at 12 weeks of 26.45 ng · (week)/
ml (p < 0.01) (Figure 3).Toxicology
No major adverse effect attributable to the drug was
found. See Additional files 1, 2 and 3 for the full toxicol-
ogy report.Figure 2 Pharmacokinetic curves of the leading formulations. PK curv
at least 10 ng/ml for the first 12 weeks and were selected to continue unti
150 μg/kg oral dose. The dotted line marks 7 ng/ml, the minimum LC50 deModelling
Mosquito survival is assumed to be distributed exponen-
tially; therefore, a population of vectors with a mean life-
span of 7.6 days will have a survival curve shown by the
dark blue line in Figure 4A. Here, 27% of mosquitoes
survive for the ten days required for the parasite to
reach its infectious sporozoite stage. After an IVM blood
meal containing 8 ng/ml, mean lifespan decreases to
1.7 days – this results in just 0.3% of mosquitoes survivinges (median and range) of the four groups that maintained IVM levels of
l week 25. The red triangle is the approximate PK curve of one single
termined in vivo for An. gambiae.
Table 4 Statistic comparison of area under the curve and
likelihood of maintaining plasma levels above 7 ng/ml
for 12 weeks
Magnitude p
AUC at 12 weeks vs DOC% (ANOVA) F = 1.98 0.16
AUC at 12 weeks vs surface (ANOVA) F = 12.37 <0.01
12 weeks over 7 ng/ml vs DOC% Chi square = 0.37 0.86
12 weeks over 7 ng/ml vs surface Chi square = 20.55 <0.01
Statistic comparison of AUC at week 12 and likelihood of maintaining plasma
levels above 7 ng/ml for 12 weeks between groups with different dose
and formulation.
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span would impact the number of infectious vectors over
time if IVM were given to 80% of the population over five
years old. Figure 4C shows the cumulative reduction in
clinical incidence in under fives and the number of in-
fectious bites received per individual (the entomological
inoculation rate (EIR)) in the six months following
treatment. An IVM product with a two-week duration
reduces the infectious vector population by over 90%
for about four weeks, which results in a 20% reduction
in clinical incidence in under fives and EIR. Infectious
vector density can be almost totally suppressed (>98%
reduction) for three months with an IVM product with
a 12-week duration such as these implantables. A formula-
tion with this duration of efficacy is estimated to reduce
clinical incidence in under fives and EIR by >60% in the
six months following implementation. Figure 4B and C
show the expected proportional increase with formula-
tions lasting for longer periods.
Discussion
These results indicate that relatively stable plasma levels
of IVM can be safely sustained in mammals for up toFigure 3 Linear regression comparing area under the curve at 12 wee
Typified coefficient 0.73. DOC: deoxycholate.24 weeks using a slow-release formulation. The insecticidal
properties of IVM make it attractive as an alternative
control tool for malaria [25] and other vector-borne
diseases, including leishmaniasis and trypanosomiasis
[27]. Its short half-life, however, could limit its wide-
spread application. Modelling shows that the time it re-
mains in plasma at levels lethal to vectors is critical for
interrupting transmission [29].
Both the AUC and the time with plasma levels above
7 ng/ml (An. gambiae’s LC50 calculated in vivo) increase
with the total elution surface of the formulations. This is
a robust parameter likely to play an important role in
the development of slow-release formulations due to its
dose-dependent effect.
Formulations with a higher content of DOC tended to
achieve markedly higher Cmax and AUC both at 12 and
24 weeks (though not statistically significant), possibly at
the expense of time with a concentration above 7 ng/ml
after 12 weeks, as seen in Figure 2. This is consistent
with the increased IVM solubility caused by DOC [35],
resulting in faster elution from the rods, i.e., ‘peaked’ PK
curves. Formulations with less DOC content have re-
lease behaviour closer to zero order.
Using the formula (DOC% x elution surface) allows for
a linear prediction of the AUC. Both factors (release area
and excipients that increase solubility) seem to have this
effect by increasing the Cmax, i.e., the ‘height’ of the curve.
Another factor likely to have a linear influence on the
AUC and the time above 7 ng/ml is the product (IVM% x
elution surface x device volume). It was not possible to
probe this theory because implants of equal volume were
used. These factors, however, are likely to influence the
AUC by increasing the time above target concentration,
i.e., the ‘length’ of the curve. These concepts may assist
in the design of different slow-release devices.ks with the product (DOC%•Surface). T (magnitude) 5.34 (p < 0.01).
Figure 4 Modelling the potential impact of slow-release ivermectin formulations. Panel A: Expected change in vector survival in the presence
of ivermectin treatment in the community. Panel B: Expected percentage change in the infectious vector density in time in the presence of different
long-lasting ivermectin formulations. Panel C: Reductions in clinical incidence and entomological inoculation rate in the six months following implementation of
a long-lasting ivermectin formulation.
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of these results to humans was not ventured due to the
disproportionate increase in adipose tissue when com-
pared to rabbit. This might initially reduce the peak
levels reached, but could effectively extend the time
above target levels as the drug is release from adipose
tissue.
No significant side effect could be attributed to the
drug in this study. Although of minor clinical signifi-
cance, future studies should assess a possible relation-
ship with increased fibrinogen. It was not possible to
find suitable data on proportional organ weight for la-
boratory rabbits of 40 weeks of age or older. The finding
of a relative large spleen at 12 weeks post intervention
should be interpreted carefully due to this lack of com-
parative standards and the absence of histological
anomalies.
IVM is a safe drug. In ongoing MDA programmes for
onchocerciasis and lymphatic filariasis, its benefits ex-
ceed the prevalence reduction of the target filariae as it
has an impact on several soil-transmitted helminths and
ectoparasites. A wider use of the drug as a public health
tool has been advocated [45,46]. With appropriate resist-
ance monitoring, assessment of pharmacokinetics and
drug interactions issues, a slow-release IVM formulation
could have additional value on the prevention and treat-
ment of these [47] and other vector-borne diseases.
There is a working delivery infrastructure for the drug
used in MDA campaigns. The evaluation of these possi-
bilities warrants joint work of the malaria and NTD
communities.
Limitations of this study
This study is intended as a proof of concept. As such it
has several limitations. PK results are given as medianand range due to the small sample size of each group.
Additionally, findings in rabbits should be interpreted
with caution due to possible differences in drug distribu-
tion and metabolism when compared with other mam-
mals. Also, the rabbits gained an average 12% of their
initial weight during the study, which could have af-
fected total body fat and the drug’s PK. The manufacture
of prototypes is not a standardized process and some PK
variation may be caused by differences in implant weight
affecting total drug content. The experiments described
in this study were conducted under good laboratory
practices (GLP), however, for budgetary reasons; the
GLP certification was not sought. The modelling work is
based on the hypothetical deployment of a new slow-
release IVM product; it aims at elucidating the potential
impact of such a long-lasting IVM formulation on mal-
aria transmission. The data used to parameterize the
model were based on mosquito mortality data taken
from laboratory studies using IVM. The impact of a new
formulation of IVM needs to be tested in the field to
fully understand the impact on transmission. Potential
challenges of implantable devices in the field include the
need for a trained worker using a sterile technique for
insertion and removal in case of adverse reactions, which
might be local or systemic. Additionally, the silicone
structure will remain in place after all the IVM and ex-
cipients have been released, the silicone itself is medical
grade and approved for indefinite implantation, but a
strategy should be in place to cover the possible user de-
mand for removal.
Knowledge gaps and future work
Setting a target plasma level was difficult because most
LC50 studies employ in vitro membrane feeds of a
blood-IVM mixture to mosquitoes. This poses a
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[48], which could lead to a higher concentration in skin
capillaries than in a vein. In fact, mosquitoes fed on sub-
jects treated with IVM have a three-fold mortality com-
pared to those feeding through a membrane [29]. A
threshold of 7 ng/ml was used as target because it is the
lowest determined LC50 for An. gambiae [30]. There is
need for a clear determination of the in vivo LC50 for
the main vector species.
Importantly, different vectors have different sensitivity
to the drug [49,50]. The LC50 varies widely between
mosquitoes; Aedes have a much higher LC50 than
Anopheles [50] and even different anopheline species in
the same area can have different LC50 [49]. This should
be taken into account when designing slow-release for-
mulations for any specific area or programme.
Using IVM as a transmission-blocking strategy poses
many ethical questions. After all, it would mean expos-
ing individuals to the possible side effects of a drug in
the name of a community benefit. Many of these ques-
tions have been debated regarding transmission-blocking
vaccines. The general consensus is that the indirect per-
sonal benefit obtained by reducing transmission at the
community level would justify the individual use of the
drug [51]. Individuals receiving IVM would also benefit
from its wide anti-parasitic effects.
The modelling results reveal the exciting potential of a
long-lasting IVM product. Even duration as short as two
weeks is estimated to reduce the total number of cases
of malaria in under fives by 20% in the following six
months. In combination with an ACT, a long-lasting
IVM drug could play an important role in interrupting
malaria transmission by suppressing the infectious vec-
tor population in the months following the intervention
and preventing resurgence.
Conclusion
This animal model shows it is technically possible to
safely sustain mosquitocidal concentrations of IVM
using a slow-release formulation. The total release area
and the proportion of the different excipients play an
important role in the delivery of the drug. The modelled
potential impact on vector population, transmission and
clinical incidence is remarkable. These findings warrant
further research on slow-release systems for IVM.Additional files
Additional file 1: Toxicology report. A complete report of the clinical
and analytical toxicological assessment of the rabbits.
Additional file 2: Vital signs and ECG data. Table with all the vital
sign and ECG measurements done as part of the toxicology workup.
Additional file 3: Biochemistry data. Table with all the biochemistry
measurements done as part of the toxicology workup.Abbreviations
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